PDCD1 and hepatocellular carcinoma: A limitation of this therapy is that PD1 expression in cancer cells does not correlate with PD1 blocker response in patients with HCC (i.e., PD1 expression was not an accurate biomarker of response to anti-PD1 therapy by itself) [32].